Feedback
Blood Group (ABO & 8 Minor Antigens) Genotyping by Microarray (INACTIVE as of 06/02/14)
2004739
Ordering Recommendation
Mnemonic
BLD GROUP8
Methodology
Polymerase Chain Reaction/ASH Microarray
Performed
Varies
Reported
5-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA). 
Specimen Preparation
Transfer 7 mL whole blood to ARUP Standard Transport Tubes. (Min: 2 mL) Specimen must be labeled with patient's name, date of birth, and date and time of draw. 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Frozen specimens. 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data


Note
This assay test includes the 9 Blood Groups: ABO, RhD/RhCE, Duffy, Kell, Kidd, Diego, Dombrock, Colton, and MNS blood groups.

This testing is recommended for the following situations:
1. Recently transfused individuals who have circulating RBCs of donor origin that interfere with the typing of self RBCs.
2. Individuals with conditions requiring frequent transfusions (eg, sickle cell disease, beta thalassemia) who develop antibodies to low-immunogenicity antigens that are present on donor RBCs. Although these antigens are usually not typed by standard serology because of their low immunogenicity, they can lead to hemolytic reactions after multiple transfusions.
3. Individuals with RhD variants with low antigen expression or with reduced numbers of antigenic epitopes (eg, weak D, D elute, partial D) where serotyping may yield inconclusive calls.
CPT Code(s)
81479
Components
Component Test Code*Component Chart NameLOINC
2004740Blood Group, ABO/8 Minor Ag, Microarray
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Bloodchip Reference

Performed at Novartis